Lenalidomide plus Rituximab as Initial Treatment for Mantle-Cell Lymphoma

BACKGROUND: Mantle-cell lymphoma is generally incurable. Initial treatment is not standardized but usually includes cytotoxic chemotherapy. Lenalidomide, an immunomodulatory compound, and rituximab, an anti-CD20 antibody, are active in patients with recurrent mantle-cell lymphoma. We evaluated lenal...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:N Engl J Med
Hlavní autoři: Ruan, Jia, Martin, Peter, Shah, Bijal, Schuster, Stephen J., Smith, Sonali M., Furman, Richard R., Christos, Paul, Rodriguez, Amelyn, Svoboda, Jakub, Lewis, Jessica, Katz, Orel, Coleman, Morton, Leonard, John P.
Médium: Artigo
Jazyk:Inglês
Vydáno: 2015
Témata:
Article
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC4710541/
https://ncbi.nlm.nih.gov/pubmed/26535512
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1056/NEJMoa1505237
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky